{"filing":{"accession_number":"0001193125-26-257593","cik":"0001674416","ticker":"CRSP","company_name":"CRISPR Therapeutics AG","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"crsp-20260604.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526257593/crsp-20260604.htm"},"events":[{"id":3413,"run_id":2990,"accession_number":"0001193125-26-257593","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"CRISPR Therapeutics held its Annual Meeting on June 4, 2026, and disclosed the final voting results for 13 proposals, including approval of financial statements, board re-elections, compensation approvals, capital increases, and auditor re-elections, with detailed tabulation of votes cast for each proposal.","company_name":"CRISPR Therapeutics AG","ticker":"CRSP","filing_date":"2026-06-04","items":[{"id":4358,"accession_number":"0001193125-26-257593","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the final voting results from CRISPR Therapeutics' Annual Meeting held on June 4, 2026, covering 13 proposals including approval of financial statements, board re-elections, compensation approvals, capital increases, and auditor re-elections. The detailed tabulation of votes cast (FOR, AGAINST, ABSTAIN, BROKER NON-VOTES) for each proposal is the hallmark of shareholder vote results disclosure, and these outcomes—particularly board composition, compensation approvals, and capital authorizations—are material to investors' assessment of corporate governance and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:59:03.626309+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":3414,"run_id":2990,"accession_number":"0001193125-26-257593","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Shareholders approved the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan on June 4, 2026, establishing a framework for future equity-based compensation awards including stock options, restricted stock units, performance shares, and other awards to directors and officers.","company_name":"CRISPR Therapeutics AG","ticker":"CRSP","filing_date":"2026-06-04","items":[{"id":4356,"accession_number":"0001193125-26-257593","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure reports shareholder approval of the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan on June 4, 2026. This is a compensatory arrangement for directors and officers that permits awards of stock options, restricted stock units, performance shares, and other equity-based compensation. Shareholder approval of a new equity incentive plan is a material disclosure under Item 5.02(e) as it establishes the framework for future executive and director compensation.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:59:03.626309+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":3415,"run_id":2990,"accession_number":"0001193125-26-257593","anchor_item_number":"5.03","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"summary":"Shareholders approved amendments to the Company's Articles of Association (Swiss corporate governance documents), effective upon registration with the Swiss Commercial Register, though the specific substantive nature of the amendments was not detailed in the disclosure.","company_name":"CRISPR Therapeutics AG","ticker":"CRSP","filing_date":"2026-06-04","items":[{"id":4357,"accession_number":"0001193125-26-257593","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"reasoning":"This disclosure reports shareholder approval of amendments to the Company's Articles of Association (Swiss corporate governance documents), effective upon registration with the Swiss Commercial Register. While Item 5.03 filings are routine administrative disclosures, the prose does not specify the substantive nature of the amendments—only that they were approved at the Annual Meeting and will be registered. Without detail on what the amendments contain, this appears to be a standard corporate governance filing rather than a material event affecting investor assessment of the registrant's financial condition or operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:59:03.626309+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4356,"accession_number":"0001193125-26-257593","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure reports shareholder approval of the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan on June 4, 2026. This is a compensatory arrangement for directors and officers that permits awards of stock options, restricted stock units, performance shares, and other equity-based compensation. Shareholder approval of a new equity incentive plan is a material disclosure under Item 5.02(e) as it establishes the framework for future executive and director compensation.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:59:03.626309+00:00","company_name":"CRISPR Therapeutics AG","ticker":"CRSP","filing_date":"2026-06-04"},{"id":4357,"accession_number":"0001193125-26-257593","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"reasoning":"This disclosure reports shareholder approval of amendments to the Company's Articles of Association (Swiss corporate governance documents), effective upon registration with the Swiss Commercial Register. While Item 5.03 filings are routine administrative disclosures, the prose does not specify the substantive nature of the amendments—only that they were approved at the Annual Meeting and will be registered. Without detail on what the amendments contain, this appears to be a standard corporate governance filing rather than a material event affecting investor assessment of the registrant's financial condition or operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:59:03.626309+00:00","company_name":"CRISPR Therapeutics AG","ticker":"CRSP","filing_date":"2026-06-04"},{"id":4358,"accession_number":"0001193125-26-257593","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the final voting results from CRISPR Therapeutics' Annual Meeting held on June 4, 2026, covering 13 proposals including approval of financial statements, board re-elections, compensation approvals, capital increases, and auditor re-elections. The detailed tabulation of votes cast (FOR, AGAINST, ABSTAIN, BROKER NON-VOTES) for each proposal is the hallmark of shareholder vote results disclosure, and these outcomes—particularly board composition, compensation approvals, and capital authorizations—are material to investors' assessment of corporate governance and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:59:03.626309+00:00","company_name":"CRISPR Therapeutics AG","ticker":"CRSP","filing_date":"2026-06-04"}]}